2016
Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming
Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolaños E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. Cancer Research 2016, 76: 5994-6005. PMID: 27550452, DOI: 10.1158/0008-5472.can-16-0549.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalBasic-Leucine Zipper Transcription FactorsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansLymphocytes, Tumor-InfiltratingMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasms, ExperimentalProgrammed Cell Death 1 ReceptorReceptor, Interferon alpha-betaRepressor ProteinsTumor MicroenvironmentTumor Necrosis Factor Receptor Superfamily, Member 9ConceptsAnti-CD137 mAbsCD8 T cellsEffector T cellsT cellsTumor lesionsMyeloid-derived suppressor cellsSelective depletion experimentsType I IFN systemTumor-infiltrating lymphocytesCombination of radiotherapyField of irradiationImmunostimulatory mAbsImmunotherapy combinationsIntracellular IFNγProimmune effectsContralateral tumorsSuppressor cellsDendritic cellsClinical evidenceRadiotherapy strategiesIrradiation regimenAntitumor effectsClinical developmentTumor siteEx vivoPredictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
Schalper KA, Kaftan E, Herbst RS. Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clinical Cancer Research 2016, 22: 2102-2104. PMID: 26957559, PMCID: PMC4940186, DOI: 10.1158/1078-0432.ccr-16-0169.Peer-Reviewed Original ResearchQuantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelakanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer. JAMA Oncology 2016, 2: 1-9. PMID: 26562159, PMCID: PMC4941982, DOI: 10.1001/jamaoncol.2015.3638.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibody SpecificityB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleFluorescent Antibody TechniqueHumansImmunohistochemistryLung NeoplasmsMaleObserver VariationPredictive Value of TestsReproducibility of ResultsRetrospective StudiesTissue Array AnalysisConceptsTumor-infiltrating lymphocytesPD-L1 expressionPD-L1 antibodiesPD-L1 protein expressionCell lung cancerPD-L1Whole tissue sectionsQuantitative immunofluorescenceLung cancerChromogenic immunohistochemistryPoor concordanceDifferent PD-L1 antibodiesHigh tumor-infiltrating lymphocytesTumor PD-L1 expressionPD-L1 protein levelsCell lung cancer biopsiesMonoclonal antibodiesCurrent consensus guidelinesProtein expressionDurable clinical responsesMain outcome measuresEarly phase trialsLung cancer biopsiesRabbit monoclonal antibodyCorresponding tissue microarrays
2015
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice
Sanmamed MF, Rodriguez I, Schalper KA, Oñate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Pérez-Gracia JL, Martín-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, Melero I. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice. Cancer Research 2015, 75: 3466-3478. PMID: 26113085, DOI: 10.1158/0008-5472.can-14-3510.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalColorectal NeoplasmsDNA-Binding ProteinsGraft vs Host DiseaseHT29 CellsHumansInterleukin Receptor Common gamma SubunitLeukocytes, MononuclearLymphocyte ActivationMiceNivolumabProgrammed Cell Death 1 ReceptorT-LymphocytesTumor Necrosis Factor Receptor Superfamily, Member 9ConceptsPeripheral blood mononuclear cellsT lymphocytesHuman T lymphocytesAllogeneic human peripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsT cell-mediated diseaseImmune checkpoint drugsImmunostimulatory monoclonal antibodiesCell-mediated diseaseRegulatory T lymphocytesHumanized murine modelBlood mononuclear cellsHumanized mouse modelPreclinical model systemsLymphocyte infiltrationTherapeutic regimenMononuclear cellsCell surface expressionCancer immunologyGastric carcinomaImmunodeficient miceMurine modelMouse modelSame patientTumor xenografts